Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.968 EUR 1.76% Market Closed
Market Cap: 164.9m EUR

Intrinsic Value

IPH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IPH stock under the Base Case scenario is 3.558 EUR. Compared to the current market price of 1.968 EUR, Innate Pharma SA is Undervalued by 45%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IPH Intrinsic Value
3.558 EUR
Undervaluation 45%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Innate Pharma SA

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
IPH
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for IPH cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Innate Pharma SA
PAR:IPH
FR
Biotechnology
Market Cap
159.3m EUR
IPO
Oct 31, 2006
FR
Biotechnology
Market Cap
159.3m EUR
IPO
Oct 31, 2006
Price
€false
EPS
€false
AI Assistant
AI Assistant
Ask me anything about Innate Pharma SA
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Innate Pharma SA

Current Assets 85.7m
Cash & Short-Term Investments 80.8m
Receivables 5m
Non-Current Assets 25.3m
Long-Term Investments 10.3m
PP&E 5.1m
Other Non-Current Assets 9.9m
Efficiency

Free Cash Flow Analysis
Innate Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Innate Pharma SA

Revenue
12.6m EUR
Operating Expenses
-64.2m EUR
Operating Income
-51.6m EUR
Other Expenses
2.1m EUR
Net Income
-49.5m EUR
Fundamental Scores

IPH Profitability Score
Profitability Due Diligence

Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
Declining ROE
18/100
Profitability
Score

Innate Pharma SA's profitability score is 18/100. The higher the profitability score, the more profitable the company is.

IPH Solvency Score
Solvency Due Diligence

Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
39/100
Solvency
Score

Innate Pharma SA's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.269 EUR with a low forecast of 2.454 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.454 EUR
25% Upside
Average
Price Target
5.269 EUR
168% Upside
Highest
Price Target
8.82 EUR
348% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Innate Pharma SA
does not pay dividends
Shareholder Yield

Current shareholder yield for IPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IPH Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one IPH stock?

The intrinsic value of one IPH stock under the Base Case scenario is 3.558 EUR.

Is IPH stock undervalued or overvalued?

Compared to the current market price of 1.968 EUR, Innate Pharma SA is Undervalued by 45%.

Back to Top